-

08:45:35 AM

Latest BIIB Stock Market News

BIIB - Biogen Inc

09/21/21 8:30 AM

Nasdaq : BIIB

Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience

33 early and late-stage clinical programs across modalities and innovative discovery platforms Uniquely positioned to lead in Alzheimer’s disease with ADUHELM ® (aducanumab-avwa) and industry-leading pipeline including Phase 3 lecanemab Potential to transform standard of care in several areas of

RHEA-AI

positive

09/20/21 7:30 AM

Nasdaq : BIIB

fda approval

FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna)

Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has

RHEA-AI

very positive

09/17/21 9:09 AM

Nasdaq : BIIB

CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis

VUMERITY is a next-generation oral fumarate with a well-characterized efficacy and safety profile Data from the Phase 3 EVOLVE-MS-2 study have demonstrated that treatment with VUMERITY results in low discontinuation rates due to its gastrointestinal (GI) tolerability profile Upon approval, VUMERITY

RHEA-AI

neutral

09/16/21 7:30 AM

Nasdaq : BIIB

clinical trial

Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy

Biogen Inc. (Nasdaq: BIIB) today announced positive topline results from its

RHEA-AI

neutral

09/15/21 7:30 AM

Nasdaq : BIIB

clinical trial

Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam)

Clinical data available to date suggest there are remaining unmet needs in some spinal muscular atrophy (SMA) patients treated with Evrysdi 1 -3 The ASCEND study aims to evaluate whether treatment with a higher dose of nusinersen has the potential to improve clinical outcomes in these patients

RHEA-AI

neutral

08/02/21 7:30 AM

Nasdaq : BIIB

clinical trial

Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis

Results show that every six-week natalizumab IV administration provides a high level of efficacy in controlling MS disease activity in patients who switched from the approved every four-week dosing regimen Data from the first prospective, randomized, controlled study of an extended dosing schedule

RHEA-AI

neutral

07/29/21 4:30 PM

Nasdaq : BIIB

Late-Breaking AAIC Presentation Explores Potential Clinical Effects Of Lecanemab (BAN2401)

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") today announced results of a longitudinal preliminary assessment of the clinical

RHEA-AI

neutral

07/29/21 4:10 PM

Nasdaq : BIIB

Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021

ICARE AD-US is an observational real-world phase 4 study designed to evaluate the safety and effectiveness of ADUHELM in clinical practice ICARE AD-US is one of three programs to generate post-approval data on ADUHELM, including the re-dosing Phase 3b EMBARK study and the planned confirmatory Phase

RHEA-AI

positive

07/26/21 4:35 PM

Nasdaq : BIIB, IONS

clinical trial

Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC

Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that topline data from a Phase 1b placebo-controlled, multiple ascending dose clinical study showed that BIIB080/IONIS-MAPT Rx met its

RHEA-AI

neutral

07/26/21 4:10 PM

Nasdaq : BIIB

Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021

Item-level analysis from EMERGE trial shows consistency in slowing decline across cognitive, functional and behavioral measures in early Alzheimer’s disease Presentations include an assessment of the correlation between reductions in amyloid beta and other biomarkers of Alzheimer’s disease and

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next

BIIB Data:

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.biogen.com
CeoMichel Vounatsos
Security nameBiogen Inc
Issue typecs
SectorManufacturing
Sic code2836
Employees9100
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address225 Binney St
StateMassachusetts
CityCambridge
Zip02142-1031
CountryUS
Phone17814642000

BIIB Description:

At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.